Effects of Nilutamide on Red Blood Cells in Prostate Cancer
Author Information
Author(s): A. Decensil, R. Torrisil, V. Fontana
Primary Institution: National Institute for Cancer Research, Genoa, Italy
Hypothesis
Does the non-steroidal anti-androgen nilutamide stimulate erythropoiesis in men with prostate cancer?
Conclusion
Nilutamide administration significantly increases haemoglobin and haematocrit levels in men with prostate cancer.
Supporting Evidence
- Nilutamide induced a significant increase in haemoglobin and haematocrit levels over time.
- The difference in haemoglobin levels between the nilutamide and LHRH agonist groups was statistically significant.
- Testosterone levels increased slightly in the nilutamide group.
Takeaway
This study found that a medicine called nilutamide can help increase red blood cells in men with prostate cancer.
Methodology
The study involved 24 men with prostate cancer treated with nilutamide, compared to 38 historical controls treated with D-tryptophan-6-LHRH.
Potential Biases
Potential bias due to the lack of randomization.
Limitations
The study lacked a randomized comparison group.
Participant Demographics
Median age of participants was 71 years, with a range of 57-78.
Statistical Information
P-Value
0.008
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website